Premium
P2‐477: Evidence for broad spectrum symptomatic efficacy across cognitive domains and potential for disease modification in Alzheimer's disease revealed by the novel alpha‐7 neuronal nicotinic receptor agonist A‐582941
Author(s) -
Gopalakrishnan Murali,
Anderson David,
Bunnelle William,
Briggs Clark,
Buccafusco Jerry,
Curzon Peter,
Decker Michael,
Hu Min,
Li Jinhe,
Malysz John,
Markosyan Stella,
Nikkel Arthur,
Radek Rich,
Robb Holly,
Bitner Robert
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.1555
Subject(s) - neuroscience , agonist , dentate gyrus , nicotinic agonist , pharmacology , nicotinic acetylcholine receptor , hippocampus , psychology , medicine , receptor
indicated that combined injection of D-galactose and NaNO2 induced memory impairment of mice. In addition, SOD and GSH-px and ATP enzyme activities decreased while MDA level and MAO-B activity increased in mouse brain. Administration of Naoyikang significantly improved the cognitive deficits and the biochemical markers mentioned above and regulated the expression of Bax and Bcl-2 and Bcl-xl mRNA in mouse brain. Part 2: The results indicated that the neural survival rate in injured neurons was lowered. Administration of Naoyikang significantly improved the neural survival rate and the biochemical markers mentioned above and decreased the expression of Bax-mRNA and increased the expression of Bcl-2 and Bcl-xl mRNA in injured neurons. Conclusions: These results suggest that Naoyikang is worth testing for further preclinical study aimed for senescence and dementia.